艾司西酞普兰片治疗抑郁症的对照研究

A Control Study of Escitalopram for Patients with Major Depression

目的 评价艾司西酞普兰片治疗抑郁症的临床疗效和安全性.方法 对符合《DSM-Ⅳ》抑郁症诊断标准的119例抑郁症患者进行艾司西酞普兰片和帕罗西汀的对照研究,其中艾司西酞普兰片62例（10 ～ 20mg/d）,帕罗西汀片组57例（20 ～ 40 mg/d）,共治疗8周.采用汉密尔顿抑郁量表（HAMD17）,汉密尔顿焦虑量表（HAMA）,蒙哥马利抑郁评定量表（MADRS）,临床总体评定量表（CGI）评定临床疗效,不良事件量表（AE）评定安全性.结果 经8周治疗后,艾司西酞普兰片组和帕罗西汀组总有效率分别为72.6％,71.9％,缓解率分别为24.2％,22.8％,2组比较,差异无统计学意义（P＞0.05）.2组的HAMD、HAMA、MADRS、CGI评分治疗前后相比较,差异有统计学意义（P＜0.001）.不良反应分析,2组药物不良反应的发生率分别为38.71％和35.09％,差异无统计学意义（P＞0.05）,常见的不良反应有恶心、口干、头昏、心悸、上腹部不适等.结论 艾司西酞普兰片治疗抑郁症疗效好,不良反应少而轻,安全性好,适合临床应用.

Objective To evaluate the efficacy and safety of escitalopram in treatment of patients with depressive disorders. Methods A control study was carried out between 119 patients who met the DSM-IV criteria of depression and depressed episode. The 62 of total patients were treated with escitalopram （10-20 mg·d-1） and the others were treated with paroxetine （20-40 mg·d-1） for 8 weeks. The efficacy was assessed by Hamilton Depression Rating Scale （HAMD）, Hamilton Anxiety Scale （HAMA）, Montgomery Depression Rating Scale （MADRS） , Clinical Global Impression （CGI） and the safety was assessed by Adverse Event Scale. Results After 8 weeks treatment, the total effective rates of escitalopram group and paroxetine group were 72.6% and 71.9% respectively, with no significant difference （P〉0.05） . The clinical curing rate of escitalopram group and paroxetine group were 24.2% and 22.8% respectively, with no significant difference （P〉0.05） . The scores of HAMD17, HAMA, MADRS and CGI in both groups decreased significantly, with statistically difference between the baseline and other observation time points （P〈0.001） . The adverse event rates of the eseitalopram group and paroxetine group were 38.71% and 35.09% respectively, with no significant difference （P 〉0.05） . The main adverse events of two groups were nausea, dry mouth, dizziness, cardiopalmus, epigastric discomfort, et al.Conclusions Escitalopram is an effective antidepressant with less side effects, better safety, and is suitable for clinical use.